Lumiracoxib for Knee Osteoarthritis Pain Relief
Author Information
Author(s): Ralf H Wittenberg, Ernest Schell, Gerhard Krehan, Roland Maeumbaed, Hans Runge, Peter Schlüter, Taiwo OA Fashola, Helen J Thurston, Klaus J Burger, Ulrich Trechsel
Primary Institution: St Elisabeth Hospital, Herten, Germany
Hypothesis
Does lumiracoxib provide better pain relief than placebo and celecoxib in patients with knee osteoarthritis?
Conclusion
Lumiracoxib significantly reduces pain in knee osteoarthritis compared to placebo and is comparable to celecoxib.
Supporting Evidence
- Lumiracoxib provided better analgesia than placebo 3–5 hours after the first dose.
- At study end, 13.9% of lumiracoxib-treated patients reported complete pain relief.
- WOMAC™ total and subscales improved for both active treatments versus placebo.
Takeaway
Lumiracoxib helps people with knee pain feel better faster than a sugar pill, and it works just as well as another common pain medicine.
Methodology
This was a randomized, double-blind, placebo-controlled study comparing lumiracoxib, celecoxib, and placebo over seven days.
Potential Biases
Potential bias due to the involvement of Novartis employees in the study.
Limitations
The study was limited to a short duration of seven days and may not reflect long-term efficacy.
Participant Demographics
Patients aged ≥50 years with moderate-to-severe symptomatic knee osteoarthritis.
Statistical Information
P-Value
0.004
Confidence Interval
1.89–9.75 mm
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website